Neuroendocrine Cancer
If it’s your first time on this website, please read the disclaimer section.
Jun 29 – Jul 06, 2026
Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS).
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This study reports the development of the SSTR-PeRForm framework for neuroendocrine tumor (NET) response assessment using a modified Delphi process involving 34 international experts. The consensus defines partial response as a ≥40% reduction in target lesion volume and progressive disease as a ≥40% volume increase or the appearance of new lesions. By prioritizing volumetric changes over standardized uptake value (SUV) metrics, the framework offers a standardized approach for evaluating therapy efficacy in cancer patients. While pending survival outcome validation, this pragmatic foundation harmonizes PET-based assessment for clinical trials and routine oncological practice.
10.1016/S1470-2045(26)00145-2
Jun 01 – Jun 08, 2026
SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.
NAT MED · Q1 JOURNAL - RANK #1/195TOP-TIER
This phase 1 trial evaluated ABBV-706, a SEZ6-targeting antibody-drug conjugate, in 288 patients with advanced solid tumors, specifically focusing on relapsed/refractory small cell lung cancer (R/R SCLC). In the R/R SCLC cohort, the objective response rate was 52%, with a median overall survival of 12.4 months at the 1.8 mg/kg dose. Safety data showed grade 3 or higher treatment-related adverse events in 61% of patients, primarily anemia and fatigue, which were dose-dependent. These findings establish 1.8 mg/kg every three weeks as the recommended phase 2 dose, offering a promising new therapeutic strategy for neuroendocrine-derived cancers.
10.1038/s41591-026-04452-0